Test drug safety and effectiveness for youth plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age must fit one of these groups: 12 to under 18, or 4 to under 12
- You’ve had plaque psoriasis for at least 6 months
- Your psoriasis is considered moderate to severe
- Your care team thinks you could benefit from light therapy (phototherapy) or whole-body treatment (systemic therapy)
- You must have already finished the Week 52 treatment period in the earlier part of this study (Part A or B) to join the long-term extension
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
This study compares two oral medications, deucravacitinib and apremilast, for adults with plaque psoriasis in Japan. It looks at how well each drug works in real-world use.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.